The best-performing hedge fund in 2015 came from an unusual place: London.» Read More
Investors are losing patience with airline stocks' underperformance as they worry industry conditions may deteriorate.
Investors fear a "black swan" catastrophic event in the financial markets right now more than ever before.
Twitter shares rallied more than 5 percent Tuesday after announcing companywide layoffs, and now traders are betting big money on a turnaround.
Improving economic data and the potential announcement of new stimulus may boost Chinese stocks in the fourth quarter, Timothy Moe said.
Third-quarter revenue is projected to fall for the third consecutive quarter, a troubling trend, according to one strategist.
"I don't like job cuts, don't get me wrong ... but I think Twitter was bloated," CNBC's Jim Cramer said.
Sharp swings in the currency markets have taken their toll on overall global wealth, shrinking it for the first time since the global financial crisis.
Conventional wisdom holds that retirees should not enter their golden years still holding a mortgage. Should they really?
Global oil demand growth is expected to slow in 2016, according to the International Energy Agency, but no one seems to have told OPEC.
Some of the names on the move ahead of the open.
Emerging markets aren't just suffering through another market rout—it's a third wave of the financial crisis, Goldman said.
The chart of the Chinese currency looks exactly like the charts of the S&P 500, the VIX and crude oil, technician Richard Ross shows.
There has been an inconsistency in the behavior of the Dow and that of the S&P 500 and Nasdaq over the past few weeks.
As earnings kick off, "Fast Money" traders looked at JPMorgan Chase, Delta Air Lines and other stocks that could pop after results.
Jim Cramer unveils the one energy stock that will let investors sleep at night, and could skyrocket much higher.
The "Fast Money" traders give their final thoughts of the day.
Despite the growing economy, Americans say hey're not spending more. Here's why.
Jim Cramer outlines why the sell-off in Eli Lilly does not make sense. Time to take advantage of a pullback opportunity?
The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.
Earnings season kicks off this week with big banks taking center stage, but it's actually two tech names grabbing the attention of options traders.